PubRank

Elliott J Mufson

Author PubWeight™ 102.13‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A 2005 4.34
2 Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002 3.84
3 A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005 3.46
4 Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 2005 3.15
5 Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2005 2.97
6 Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2007 2.43
7 Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem 2005 2.36
8 Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci 2003 2.14
9 Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann Neurol 2002 1.82
10 Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J Neurochem 2006 1.67
11 Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J Neuropathol Exp Neurol 2006 1.56
12 Activation of caspase-6 in aging and mild cognitive impairment. Am J Pathol 2007 1.53
13 Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Biol Psychiatry 2010 1.49
14 Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J Neuropathol Exp Neurol 2004 1.48
15 Neuronal LR11/sorLA expression is reduced in mild cognitive impairment. Ann Neurol 2007 1.45
16 Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann Neurol 2004 1.43
17 Distribution of estrogen receptor alpha and beta immunoreactive profiles in the postnatal rat brain. Brain Res Dev Brain Res 2003 1.43
18 Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord 2010 1.39
19 The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J Neuropathol Exp Neurol 2005 1.35
20 Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol 2002 1.32
21 Nurr1 in Parkinson's disease and related disorders. J Comp Neurol 2006 1.27
22 U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease. Proc Natl Acad Sci U S A 2013 1.23
23 Single cell gene expression profiling in Alzheimer's disease. NeuroRx 2006 1.22
24 Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J Neurosci 2009 1.19
25 A novel fluorescent probe that is brain permeable and selectively binds to myelin. J Histochem Cytochem 2006 1.19
26 Alpha7 nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease. Arch Neurol 2007 1.16
27 Single-cell gene expression analysis: implications for neurodegenerative and neuropsychiatric disorders. Neurochem Res 2004 1.16
28 Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer's disease. Invest Ophthalmol Vis Sci 2008 1.12
29 Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. J Neurochem 2010 1.10
30 Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2011 1.09
31 Improved detection of substantia nigra pathology in Alzheimer's disease. J Histochem Cytochem 2002 1.08
32 Cholinergic forebrain degeneration in the APPswe/PS1DeltaE9 transgenic mouse. Neurobiol Dis 2007 1.08
33 Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology. J Alzheimers Dis 2003 1.07
34 Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PS1DeltaE9 transgenic mice. J Neurosci 2005 1.07
35 Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. Am J Pathol 2011 1.07
36 Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. J Neurochem 2006 1.06
37 Estrogen restores cognition and cholinergic phenotype in an animal model of Down syndrome. Physiol Behav 2002 1.04
38 Regional selectivity of rab5 and rab7 protein upregulation in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2010 1.04
39 Brainstem Alzheimer's-like pathology in the triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2009 1.03
40 Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 2003 1.02
41 Increased matrix metalloproteinase 9 activity in mild cognitive impairment. J Neuropathol Exp Neurol 2009 1.01
42 Contribution of changes in ubiquitin and myelin basic protein to age-related cognitive decline. Neurosci Res 2004 0.99
43 Staging of Alzheimer's pathology in triple transgenic mice: a light and electron microscopic analysis. Int J Alzheimers Dis 2010 0.98
44 Galanin in Alzheimer disease. Mol Interv 2003 0.97
45 Galanin fiber hypertrophy within the cholinergic nucleus basalis during the progression of Alzheimer's disease. Dement Geriatr Cogn Disord 2006 0.97
46 DHA diet reduces AD pathology in young APPswe/PS1 Delta E9 transgenic mice: possible gender effects. J Neurosci Res 2010 0.96
47 Superior frontal cortex cholinergic axon density in mild cognitive impairment and early Alzheimer disease. Arch Neurol 2007 0.95
48 Hippocampal drebrin loss in mild cognitive impairment. Neurodegener Dis 2012 0.94
49 Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis 2013 0.93
50 Galanin fiber hyperinnervation preserves neuroprotective gene expression in cholinergic basal forebrain neurons in Alzheimer's disease. J Alzheimers Dis 2009 0.92
51 Galanin inhibits tyrosine hydroxylase expression in midbrain dopaminergic neurons. J Neurochem 2002 0.91
52 Reduction of choline acetyltransferase activity in primary visual cortex in mild to moderate Alzheimer's disease. Arch Neurol 2005 0.91
53 Galanin hyperinnervation upregulates choline acetyltransferase expression in cholinergic basal forebrain neurons in Alzheimer's disease. Neurodegener Dis 2008 0.89
54 Cholinotrophic basal forebrain system alterations in 3xTg-AD transgenic mice. Neurobiol Dis 2010 0.88
55 Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease. Arch Neurol 2009 0.86
56 Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. J Chem Neuroanat 2011 0.86
57 Galanin overexpressing transgenic mice. Neuropeptides 2002 0.86
58 Excitotoxic and metabolic damage to the rodent striatum: role of the P75 neurotrophin receptor and glial progenitors. J Comp Neurol 2002 0.86
59 Synapse stability in the precuneus early in the progression of Alzheimer's disease. J Alzheimers Dis 2013 0.85
60 Rac1b increases with progressive tau pathology within cholinergic nucleus basalis neurons in Alzheimer's disease. Am J Pathol 2011 0.85
61 Sex differences in the cholinergic basal forebrain in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease. Brain Pathol 2013 0.84
62 Maternal choline supplementation differentially alters the basal forebrain cholinergic system of young-adult Ts65Dn and disomic mice. J Comp Neurol 2014 0.83
63 Gender differences in neurotrophin and glutamate receptor expression in cholinergic nucleus basalis neurons during the progression of Alzheimer's disease. J Chem Neuroanat 2011 0.83
64 Effects of estrogen replacement therapy on cholinergic basal forebrain neurons and cortical cholinergic innervation in young and aged ovariectomized rhesus monkeys. J Comp Neurol 2004 0.83
65 Distribution of high affinity choline transporter immunoreactivity in the primate central nervous system. J Comp Neurol 2003 0.83
66 Neuroprotective role for galanin in Alzheimer's disease. EXS 2010 0.83
67 Alzheimer's disease pathology in the neocortex and hippocampus of the western lowland gorilla (Gorilla gorilla gorilla). J Comp Neurol 2013 0.83
68 Effects of aromatase inhibition versus gonadectomy on hippocampal complex amyloid pathology in triple transgenic mice. Neurobiol Dis 2011 0.82
69 Effect of neocortical and hippocampal amyloid deposition upon galaninergic and cholinergic neurites in AβPPswe/PS1ΔE9 mice. J Alzheimers Dis 2011 0.82
70 A novel approach for long-term oral drug administration in animal research. J Neurosci Methods 2010 0.82
71 Cognitive performance correlates with cortical isopeptide immunoreactivity as well as Alzheimer type pathology. J Alzheimers Dis 2008 0.81
72 Increased metabolic activity in nucleus basalis of Meynert neurons in elderly individuals with mild cognitive impairment as indicated by the size of the Golgi apparatus. J Neuropathol Exp Neurol 2006 0.81
73 Endogenous galanin protects mouse hippocampal neurons against amyloid toxicity in vitro via activation of galanin receptor-2. J Alzheimers Dis 2011 0.80
74 Galanin receptor over-expression within the amygdala in early Alzheimer's disease: an in vitro autoradiographic analysis. J Chem Neuroanat 2002 0.80
75 U1 small nuclear ribonucleoproteins (snRNPs) aggregate in Alzheimer's disease due to autosomal dominant genetic mutations and trisomy 21. Mol Neurodegener 2014 0.80
76 Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice. Int J Physiol Pathophysiol Pharmacol 2012 0.79
77 Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease. J Clin Immunol 2014 0.79
78 Hippocampal endosomal, lysosomal, and autophagic dysregulation in mild cognitive impairment: correlation with aβ and tau pathology. J Neuropathol Exp Neurol 2015 0.78
79 Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer's Disease. Curr Alzheimer Res 2016 0.78
80 Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome. Curr Alzheimer Res 2016 0.77
81 Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease. J Chem Neuroanat 2010 0.77
82 Association of early experience with neurodegeneration in aged primates. Neurobiol Aging 2009 0.77
83 PUTATIVE CSF PROTEIN BIOMARKER CANDIDATES FOR AMNESTIC MILD COGNITIVE IMPAIRMENT. Transl Neurosci 2010 0.77
84 Evidence for Mitochondrial UPR Gene Activation in Familial and Sporadic Alzheimer's Disease. Curr Alzheimer Res 2016 0.75
85 Neuronal LR11 expression does not differentiate between clinically-defined Alzheimer's disease and control brains. PLoS One 2012 0.75
86 Frontal Cortex and Hippocampal γ-Secretase Activating Protein Levels in Prodromal Alzheimer Disease. Neurodegener Dis 2017 0.75
87 RNA amplification of bromodeoxyuridine labeled newborn neurons in the monkey hippocampus. J Neurosci Methods 2004 0.75
88 Regulator of Cell Cycle (RGCC) expression during the progression of Alzheimers disease. Cell Transplant 2016 0.75